Use of quinone Q10 for the treatment of ocular diseases

Details Use of quinone Q10 for the treatment of ocular diseases Use of quinone Q10 for the treatment of ocular diseases

2006-04-18

2006-04-18

Lilling, Herbert J. (Department: 1651)

Drug, bio-affecting and body treating compositions

Enzyme or coenzyme containing

Reexamination Certificate

active

07029672

ABSTRACT:
The present invention relates to the use of Coenzyme Q10or functionally equivalent derivatives thereof, through topical or systemic administration, for the prevention, the treatment and/or attenuation of degenerative ocular pathologies, said pathologies being of an heredofamilial, inflammatory, dysmetabolic, senile age-related nature, the degenerative process deriving from apoptotic events caused by hypoxia or other detrimental stimuli due to ischemia or to the lack of trophic factors.

REFERENCES:
patent: 4871742 (1989-10-01), Boone et al.
patent: 6403116 (2002-06-01), Anderson et al.
patent: 6417233 (2002-07-01), Sears et al.
patent: 6441050 (2002-08-01), Chopra
patent: 6787572 (2004-09-01), Brancato et al.
patent: 2002/0119936 (2002-08-01), Nyce
patent: 1299578 (2000-03-01), None
patent: WO 96/17626 (1996-06-01), None
patent: WO 00/23069 (2000-04-01), None
patent: WO 00/57871 (2000-10-01), None
patent: WO 01/37851 (2001-05-01), None
patent: WO 01/37851 (2001-05-01), None
patent: WO 01/37851 (2001-05-01), None
patent: WO 02/17879 (2002-03-01), None
Takahashi et al Biosis Abstract 1989:478937 “Effect of Coenzyme Q-10 on Hemodynamic response to ocular Timolol” J. Cardiovascular Pharm.(1989) vol. 14. No. 3, pp 462-46.
Kuwayama: “Experimental Studies on Antioxidative Effect of Coenzyme Q10on the Retina,” pp. 137-147;Nagoya Med. J. (1984) 29.
Rotig et al: “Quinone-responsive multiple respiratory-chain dysfunction due to widespread coenzyme Q10deficiency,” pp. 391-395,The Lancet, vol. 356, Jul. 29, 2000.
Feher et al: IL Coenzima Q10Migliora La Funzione Visiva Nella Retinite Pigmentosa (Studio Preliminare), pp. 31-33,Clin. Ocul. n. Jan. 1996.
Benes: “Gradual Painless Visual Loss,” pp. 47-85,Visual and Auditory Challenges, vol. 15, No. 1, Feb. 1999.
Blasi et al: “Does Coenzyme Q10Play A Role in Opposing Oxidative Stress in Patients with Age-Related Macular Degeneration?” pp. 51-54,Ophthalmologica2001; 215-:51-54.
Florence: “The role of free radicals in disease,” pp. 3-7,The Ida Mann Lecture. Presented at the 24thScientific Congress of The Royal Australian College of Ophthalmologists, Nov. 1992.
Kerrigan et al Archives of Ophthalmology vol. 115(8), Aug. 1997 pp. 1031-1035 TUNEL-Positive Ganglion Cells in Human Primary Open-angle Glaucoma.
Gross et al Survey of Ophthalmology, vol. 43 supp. 1, Jun. 1999 pp S162-S170 Retinal Ganglion Cell Dysfunction Induced by Hypoxia and Glutamate: Potential Neuroprotective Effects of β-Blockers.
Nickells Survey of Ophthalmology, vol. 43, supp 1, Jun. 1999 Apoptosis of Retinal Ganglion Cells in Glaucoma: An Update of the Molecular Pathways Involved in Cell Death.
Blankenberg et al Blood, vol. 89, No. 10 May 1997, pp. 3778-3786 Quantitative Analysis of Apoptotic Cell Death Using Proton Nuclear Magnetic Resonance Spectroscopy.
D.W. Nicholson, NATURE, vol. 407, Oct. 12, 2000 pp. 810-816.
A. Tempestini et al., European Journal of Ophthalmology, vol. 13, Suppl. 3, 2003 p. 1, 2, 6, 7, 8.
G. Carella European Journal of Ophthalmology vol. 13, Suppl. 3, 2003 pp. 51, 56, 58, 59, S10.

Affiliated with

Also associated with

Rating

Use of quinone Q10 for the treatment of ocular diseases does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Use of quinone Q10 for the treatment of ocular diseases, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of quinone Q10 for the treatment of ocular diseases will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3612901